Elanix Biotechnologies

Elanix Biotechnologies is a life sciences company focused on tissue regeneration products. It is dedicated to the development and commercialization of products for acute wound care, dermatology, and gynecological applications, as well as providing cell technology services. Founded in 2013 as a spin-off from the University Hospital of Lausanne (CHUV) in Switzerland, the company aims to commercialize its patented progenitor cell technology. Progenitor cells are fully differentiated, immune-neutral cells and are highly effective inducers of tissue growth and healing. Elanix owns GMP-certified Master and Working cell banks containing large quantities of cells. The company is headquartered in Nyon, Switzerland, with an office in Wiesbaden.